{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:43:30Z","timestamp":1769816610413,"version":"3.49.0"},"reference-count":198,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0393-3","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T11:28:13Z","timestamp":1446031693000},"page":"163-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity"],"prefix":"10.1016","volume":"13","author":[{"given":"Eleni I.","family":"Kampylafka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0393-3_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/ard.2008.106351","article-title":"Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus","volume":"69","author":"Hanly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/qjmed\/hcl005","article-title":"Neurological involvement in patients with rheumatic disease","volume":"99","author":"Sofat","year":"2006","journal-title":"QJM"},{"key":"10.1007\/s13311-015-0393-3_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clineuro.2005.11.009","article-title":"Central nervous system involvement in systemic connective tissue diseases","volume":"108","author":"Cikes","year":"2006","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib4","doi-asserted-by":"crossref","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599\u2013608","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"10.1007\/s13311-015-0393-3_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2010.62","article-title":"Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations","volume":"6","author":"Bertsias","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X","article-title":"Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation","volume":"45","author":"Ainiala","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib7","first-page":"2156","article-title":"Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance","volume":"31","author":"Hanly","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10067-011-1841-z","article-title":"Beyond the joints: neurological involvement in rheumatoid arthritis","volume":"31","author":"Ramos-Remus","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-015-0393-3_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0889-857X(05)70364-1","article-title":"Methotrexate use in miscellaneous inflammatory diseases","volume":"23","author":"Wilke","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1007\/s13311-015-0393-3_bib11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1526-0968.2003.00032.x","article-title":"The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus","volume":"7","author":"Neuwelt","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1007\/s13311-015-0393-3_bib13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0393-3_bib14","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","article-title":"Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy","volume":"43","author":"Russell","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib17","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00296-005-0068-1","article-title":"SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)","volume":"26","author":"Armstrong","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1007\/s13311-015-0393-3_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Behcet's disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/NRL.0b013e3181ebe59f","article-title":"Peripheral nervous system manifestations of Sjogren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies","volume":"16","author":"Birnbaum","year":"2010","journal-title":"Neurologist"},{"key":"10.1007\/s13311-015-0393-3_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clineuro.2010.03.023","article-title":"Antiphospholipid syndrome and central nervous system","volume":"112","author":"Mayer","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib22","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrneurol.2014.148","article-title":"Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers","volume":"10","author":"Jeltsch-David","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10067-004-1046-9","article-title":"Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature","volume":"24","author":"Milstone","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence","volume":"41","author":"Narvaez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40259-013-0031-8","article-title":"Belimumab therapy in systemic lupus erythematosus","volume":"27","author":"Zouali","year":"2013","journal-title":"BioDrugs: clinical immunotherapeutics, Biopharmaceuticals Gene Ther"},{"key":"10.1007\/s13311-015-0393-3_bib28","doi-asserted-by":"crossref","first-page":"e55843","DOI":"10.1371\/journal.pone.0055843","article-title":"Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients","volume":"8","author":"Kampylafka","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0393-3_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/RHU.0b013e31820e7c8d","article-title":"Chorea in systemic lupus erythematosus","volume":"17","author":"Baizabal-Carvallo","year":"2011","journal-title":"J Clin Rheumatol: Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1007\/s13311-015-0393-3_bib30","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.59.2.120","article-title":"Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature","volume":"59","author":"Kovacs","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib33","first-page":"280","article-title":"Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies","volume":"31","author":"D'Cruz","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2005.08.008","article-title":"Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome","volume":"35","author":"Vina","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/BOR.0b013e328363eaf1","article-title":"Pathogenesis and treatment of CNS lupus","volume":"25","author":"Fanouriakis","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-014-2679-y","article-title":"Detection of asymptomatic cranial neuropathies in patients with systemic lupus erythematosus and their relation to antiribosomal P antibody levels and disease activity","volume":"33","author":"Gaber","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib40","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jns.2014.09.035","article-title":"Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study","volume":"347","author":"Kosmidis","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0393-3_bib42","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebophase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib45","doi-asserted-by":"crossref","first-page":"239398","DOI":"10.1155\/2014\/239398","article-title":"Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage","volume":"2014","author":"Carecchio","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1007\/s13311-015-0393-3_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3349\/ymj.2003.44.2.323","article-title":"Transverse myelitis in a patient with primary antiphospholipid syndrome","volume":"44","author":"Lee","year":"2003","journal-title":"Yonsei Med J"},{"key":"10.1007\/s13311-015-0393-3_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semarthrit.2010.05.004","article-title":"Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature","volume":"40","author":"Rodrigues","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1191\/096120399678847524","article-title":"Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes","volume":"8","author":"Chapman","year":"1999","journal-title":"Lupus"},{"key":"10.1007\/s13311-015-0393-3_bib49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1007\/s13311-015-0393-3_bib50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3899\/jrheum.110800","article-title":"Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome","volume":"39","author":"Grika","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib51","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMe038131","article-title":"Treatment of the antiphospholipid syndrome","volume":"349","author":"Lockshin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib52","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1259\/bjr.72.856.10474506","article-title":"Pachymeningitis and optic neuritis in rheumatoid arthritis: MRI findings","volume":"72","author":"Agildere","year":"1999","journal-title":"Br J Radiol"},{"key":"10.1007\/s13311-015-0393-3_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF03324795","article-title":"A case of normal-pressure hydrocephalus associated with rheumatoid arthritis","volume":"22","author":"Catananti","year":"2010","journal-title":"Aging Clin Exp Res"},{"key":"10.1007\/s13311-015-0393-3_bib55","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2169\/internalmedicine.49.3492","article-title":"Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions","volume":"49","author":"Ikeda","year":"2010","journal-title":"Intern Med"},{"key":"10.1007\/s13311-015-0393-3_bib56","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00296-009-1266-z","article-title":"Unusual central nervous system involvement of rheumatoid arthritis: successful treatment with steroid and azathioprine","volume":"31","author":"Inan","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1007\/s13311-015-0393-3_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jbspin.2006.08.004","article-title":"Cerebral vasculitis in a patient with rheumatoid arthritis","volume":"74","author":"Mrabet","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1007\/s13311-015-0393-3_bib58","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/art.24577","article-title":"Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab","volume":"60","author":"Schmid","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10067-003-0788-0","article-title":"Rheumatoid meningitis: an autopsy report and review of the literature","volume":"22","author":"Kato","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib60","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.wnl.0000257824.72457.91","article-title":"Clinical manifestations and treatment of rheumatoid pachymeningitis","volume":"68","author":"Starosta","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/PL00011193","article-title":"Pachymeningitis and optic neuritis in rheumatoid arthritis: successful treatment with cyclophosphamide","volume":"20","author":"Yucel","year":"2001","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib62","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/ard.2005.042093","article-title":"Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab","volume":"65","author":"Chou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib63","first-page":"1960","article-title":"Rheumatoid nodulosis of the meninges","volume":"21","author":"Karam","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/0268869031000153170","article-title":"Extradural spinal cord compression by rheumatoid nodule","volume":"17","author":"Tsegaye","year":"2003","journal-title":"Br J Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib65","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00256-008-0484-x","article-title":"MRI of cervical spine injuries complicating ankylosing spondylitis","volume":"37","author":"Koivikko","year":"2008","journal-title":"Skeletal Radiol"},{"key":"10.1007\/s13311-015-0393-3_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/ard.47.2.173-a","article-title":"Atlantoaxial subluxation and spinal cord compression in psoriatic arthropathy","volume":"47","author":"Santavirta","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib67","first-page":"173","article-title":"Intravenous corticosteroid therapy of cervical cord compression in rheumatoid arthritis","volume":"10","author":"Louthrenoo","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib68","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/art.24597","article-title":"Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis","volume":"60","author":"Cornec","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00415-009-5361-6","article-title":"Acute transverse myelitis in psoriatic arthritis","volume":"257","author":"Rath","year":"2010","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0248-8663(99)83033-1","article-title":"Polyradicular lesion revealing ankylosing spondylarthritis","volume":"20","author":"Guilloton","year":"1999","journal-title":"Rev Med Interne"},{"key":"10.1007\/s13311-015-0393-3_bib71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jocn.2006.07.005","article-title":"Lumbar radiculopathy in ankylosing spondylitis with dural ectasia","volume":"14","author":"Kotil","year":"2007","journal-title":"J Clin Neurosci"},{"key":"10.1007\/s13311-015-0393-3_bib72","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0002-9343(84)90654-5","article-title":"Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis","volume":"76","author":"Scott","year":"1984","journal-title":"Am J Med"},{"key":"10.1007\/s13311-015-0393-3_bib73","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/rheumatology\/39.12.1436","article-title":"Mononeuritis secondary to rheumatoid arthritis responds to etanercept","volume":"39","author":"Richter","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.62.6.587","article-title":"Successful treatment of severe rheumatoid vasculitis by infliximab","volume":"62","author":"Unger","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib75","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14397595.2013.874748","article-title":"Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis","volume":"25","author":"Iijima","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib77","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3109\/s10165-011-0559-8","article-title":"The rapid efficacy of abatacept in a patient with rheumatoid vasculitis","volume":"22","author":"Fujii","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib78","doi-asserted-by":"crossref","unstructured":"Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev 2015","DOI":"10.1016\/j.autrev.2015.04.003"},{"key":"10.1007\/s13311-015-0393-3_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/BOR.0000000000000126","article-title":"Rheumatoid vasculitis: an update","volume":"27","author":"Makol","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib80","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/keq111","article-title":"Central nervous system involvement in Sjogren's syndrome: unusual, but not unremarkable\u2013clinical, serological characteristics and outcomes in a large cohort of Italian patients","volume":"49","author":"Massara","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib81","doi-asserted-by":"crossref","first-page":"e84605","DOI":"10.1371\/journal.pone.0084605","article-title":"Neurological involvement in primary Sjogren syndrome: a focus on central nervous system","volume":"9","author":"Morreale","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-015-0393-3_bib82","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","article-title":"Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients","volume":"83","author":"Delalande","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1007\/s13311-015-0393-3_bib83","first-page":"29","article-title":"Neurological involvement in Primary Sjogren Syndrome","volume":"38","author":"Teixeira","year":"2013","journal-title":"Acta Reumatol Port"},{"key":"10.1007\/s13311-015-0393-3_bib84","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1600-0404.1993.tb04242.x","article-title":"Aseptic meningoencephalitis in primary Sjogren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy","volume":"88","author":"Gerraty","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-015-0393-3_bib85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/hcr218","article-title":"White matter abnormalities in primary Sjogren syndrome","volume":"105","author":"Akasbi","year":"2012","journal-title":"QJM"},{"key":"10.1007\/s13311-015-0393-3_bib86","first-page":"208","article-title":"Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: results from the AIR registry","volume":"30","author":"Mekinian","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib87","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sjogren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"10.1007\/s13311-015-0393-3_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coms.2013.09.009","article-title":"Management of extraglandular manifestations of primary Sjogren's syndrome","volume":"26","author":"Wu","year":"2014","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1007\/s13311-015-0393-3_bib89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejim.2013.10.005","article-title":"Immunological profiles determine neurological involvement in Sjogren's syndrome","volume":"25","author":"Jamilloux","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1007\/s13311-015-0393-3_bib90","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jnnp.2010.222109","article-title":"Peripheral neuropathies in Sjogren syndrome: a new reappraisal","volume":"82","author":"Pavlakis","year":"2011","journal-title":"J Neurol neurosurgery Psychiatr"},{"key":"10.1007\/s13311-015-0393-3_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaut.2012.01.003","article-title":"Peripheral neuropathies in Sjogren's syndrome: a critical update on clinical features and pathogenetic mechanisms","volume":"39","author":"Pavlakis","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-015-0393-3_bib92","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mus.20100","article-title":"Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies)","volume":"30","author":"Kuntzer","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0393-3_bib93","first-page":"503","article-title":"Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome","volume":"60","author":"Takahashi","year":"2003","journal-title":"IV immunoglobulin. Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib94","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.59.7.1113","article-title":"Severe sensory neuronopathy responsive to infliximab in primary Sjogren's syndrome","volume":"59","author":"Caroyer","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib95","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000052142","article-title":"Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjogren's syndrome","volume":"45","author":"Chen","year":"2001","journal-title":"European Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10286-009-0012-7","article-title":"Autoimmune autonomic ganglionopathy: treatment by plasma exchanges andrituximab","volume":"19","author":"Imrich","year":"2009","journal-title":"Clin Auton Res"},{"key":"10.1007\/s13311-015-0393-3_bib97","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp.2004.049502","article-title":"Interferon alfa treatment for Sjogren's syndrome associated neuropathy","volume":"76","author":"Yamada","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0393-3_bib98","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh605","article-title":"The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy","volume":"128","author":"Mori","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0393-3_bib99","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1474-4422(05)70249-0","article-title":"An update on the classification and treatment of vasculitic neuropathy","volume":"4","author":"Schaublin","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MD.0b013e31820fd2d1","article-title":"Peripheral neuropathies associated with primary Sjogren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy","volume":"90","author":"Sene","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1007\/s13311-015-0393-3_bib101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","article-title":"Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry","volume":"71","author":"Mekinian","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib102","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"10.1007\/s13311-015-0393-3_bib104","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CND.0b013e3181c50513","article-title":"Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjogren's syndrome after Rituximab therapy","volume":"11","author":"Botez","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1007\/s13311-015-0393-3_bib105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/s10165-009-0180-2","article-title":"Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome","volume":"19","author":"Wakasugi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib106","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s100670050105","article-title":"Neurological involvement in primary Sjogren's syndrome: clinical and instrumental evaluation in a cohort of Italian patients","volume":"18","author":"Govoni","year":"1999","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib107","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2013.05.002","article-title":"Neurologic involvement in scleroderma: a systematic review","volume":"43","author":"Amaral","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib108","doi-asserted-by":"crossref","first-page":"691314","DOI":"10.1155\/2012\/691314","article-title":"Successful treatment of hemifacial myokymia and dystonia associated to linear scleroderma \u201cen coup de sabre\u201d with repeated botox injections","volume":"2012","author":"Canas","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1007\/s13311-015-0393-3_bib109","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejpn.2007.12.001","article-title":"Hippocampal atrophy and developmental regression as first sign of linear scleroderma \u201cen coup de sabre\u201d","volume":"12","author":"Verhelst","year":"2008","journal-title":"Eur J Paediatr Neurol: EJPN: Off J Eur Paediatr Neurol Soc"},{"key":"10.1007\/s13311-015-0393-3_bib110","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2005-0470","article-title":"Linear scleroderma en coup de sabre with associated neurologic abnormalities","volume":"117","author":"Holland","year":"2006","journal-title":"Pediatrics"},{"key":"10.1007\/s13311-015-0393-3_bib111","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1067\/S0190-9622(03)00901-0","article-title":"Scleroderma en coup de sabre with central nervous system and ophthalmologic involvement: treatment of ocular symptoms with interferon gamma","volume":"49","author":"Obermoser","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1007\/s13311-015-0393-3_bib112","first-page":"704","article-title":"Spinal cord compression by ectopic calcinosis in scleroderma","volume":"23","author":"Lima","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-013-0383-6","article-title":"Classification of ANCA-associated vasculitis","volume":"15","author":"Khan","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1007\/s13311-015-0393-3_bib115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2009.05.017","article-title":"The clinical spectrum of the neurological involvement in vasculitides","volume":"285","author":"Rossi","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0393-3_bib116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00002512-200825040-00002","article-title":"Diagnosis and treatment of giant cell arteritis","volume":"25","author":"Cantini","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1007\/s13311-015-0393-3_bib117","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib118","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib119","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e318294b477","article-title":"Multifocal VZV vasculopathy with temporal artery infection mimics giant cell arteritis","volume":"80","author":"Nagel","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jns.2013.09.034","article-title":"Varicella zoster virus in the temporal artery of a patient with giant cell arteritis","volume":"335","author":"Nagel","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0393-3_bib121","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","article-title":"BSR and BHPR guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib122","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib123","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","article-title":"Takayasu arteritis","volume":"120","author":"Kerr","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-015-0393-3_bib124","first-page":"537","article-title":"Relapsing spinal cord and cranial nerve syndromes in Takayasu's arteritis","volume":"37","author":"Gupta","year":"1989","journal-title":"J Assoc Phys India"},{"key":"10.1007\/s13311-015-0393-3_bib125","first-page":"735","article-title":"Ischemic myelopathy in Takayasu's disease","volume":"33","author":"Nair","year":"1985","journal-title":"J Assoc Phys India"},{"key":"10.1007\/s13311-015-0393-3_bib126","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib127","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib128","first-page":"406963","article-title":"Remission achieved in refractory advanced takayasu arteritis using rituximab","volume":"2012","author":"Ernst","year":"2012","journal-title":"Case Rep Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib129","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Res"},{"key":"10.1007\/s13311-015-0393-3_bib130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jns.2010.10.016","article-title":"Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: case report and review of the literature","volume":"301","author":"Mencacci","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0393-3_bib131","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/rheumatology\/keu336","article-title":"Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes","volume":"54","author":"De Luna","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib132","first-page":"S62","article-title":"Anterior ischaemic optic neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a case report and review of the literature","volume":"32","author":"Padovano","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib133","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib134","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib135","first-page":"608942","article-title":"Wegener's granulomatosis presenting with pachymeningitis: clinical and imaging remission by rituximab","volume":"2011","author":"Just","year":"2011","journal-title":"ISRN Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib136","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.rhu.0000191217.11688.3c","article-title":"Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab","volume":"11","author":"Memet","year":"2005","journal-title":"J Clin Rheumatol: Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1007\/s13311-015-0393-3_bib137","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: a systematic review","volume":"43","author":"Silva-Fernandez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib138","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg-Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-015-0393-3_bib139","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-015-0393-3_bib140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.64.3.382","article-title":"Behcet's syndrome: a report of 41 patients with emphasis on neurological manifestations","volume":"64","author":"Farah","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0393-3_bib141","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","article-title":"Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease","volume":"42","author":"Tursen","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1007\/s13311-015-0393-3_bib142","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","article-title":"Neuro-Behcet's disease: epidemiology, clinical characteristics, and management","volume":"8","author":"Al-Araji","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib143","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.74.5.608","article-title":"Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq","volume":"74","author":"Al-Araji","year":"2003","journal-title":"J Neurol neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0393-3_bib144","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1468-1331.2006.01613.x","article-title":"Neuro-Behcet's disease in Caucasians: a study of 22 patients","volume":"14","author":"Joseph","year":"2007","journal-title":"Eur J Neurol"},{"issue":"Pt 11","key":"10.1007\/s13311-015-0393-3_bib145","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","article-title":"Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients","volume":"122","author":"Akman-Demir","year":"1999","journal-title":"The Neuro-Behcet Study Group. Brain"},{"key":"10.1007\/s13311-015-0393-3_bib146","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.42.3.614","article-title":"Cerebral venous thrombosis in Behcet's disease: clinical study and long-term follow-up of 25 cases","volume":"42","author":"Wechsler","year":"1992","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib147","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11910-012-0316-1","article-title":"Neurological complications of Behcet's syndrome","volume":"12","author":"Kidd","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-015-0393-3_bib148","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.neurol.2011.09.006","article-title":"Neurological manifestations of Behcet's disease: evaluation of 40 patients treated by cyclophosphamide","volume":"168","author":"Ait Ben Haddou","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"10.1007\/s13311-015-0393-3_bib149","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Behcet's disease: beyond anti-TNF therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators of inflammation"},{"key":"10.1007\/s13311-015-0393-3_bib150","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib151","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib152","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0002-9343(63)90078-0","article-title":"Neurologic aspects of Behcet's disease. Case report and review of the literature","volume":"34","author":"Schotland","year":"1963","journal-title":"Am J Med"},{"key":"10.1007\/s13311-015-0393-3_bib153","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1756-185X.2009.01420.x","article-title":"Successful use of infliximab in a patient with neuro-Behcet's disease","volume":"12","author":"Abalos-Medina","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib154","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Behcet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Behcet's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0393-3_bib156","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib157","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Behcet's disease: case series and literature review","volume":"30","author":"Borhani Haghighi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib158","doi-asserted-by":"crossref","unstructured":"Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol 2013","DOI":"10.1007\/s10067-013-2443-8"},{"key":"10.1007\/s13311-015-0393-3_bib159","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/NRL.0b013e31805778d1","article-title":"Peripheral nervous system involvement in patients with Behcet disease","volume":"13","author":"Atasoy","year":"2007","journal-title":"Neurologist"},{"key":"10.1007\/s13311-015-0393-3_bib160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF02030351","article-title":"Mononeuritis multiplex in incomplete Behcet's disease: a case report and the review of the literature","volume":"8","author":"Takeuchi","year":"1989","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib161","first-page":"88","article-title":"Coexistence of Guillain-Barre syndrome and Behcet's disease","volume":"31","author":"Shugaiv","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib162","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1212\/WNL.61.1.104","article-title":"Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus","volume":"61","author":"Chau","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib163","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","article-title":"Psychiatric complications of treatment with corticosteroids: review with case report","volume":"65","author":"Kenna","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1007\/s13311-015-0393-3_bib164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J Endocrinol"},{"key":"10.1007\/s13311-015-0393-3_bib165","first-page":"645","article-title":"Inflammatory and toxic myopathies","volume":"5","author":"Dalakas","year":"1992","journal-title":"Curr Opin Neurol Neurosurg"},{"key":"10.1007\/s13311-015-0393-3_bib166","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2010.02.025","article-title":"Freire de Carvalho J","volume":"78","author":"Pereira","year":"2011","journal-title":"Glucocorticoid-induced myopathy. Joint Bone Spine"},{"key":"10.1007\/s13311-015-0393-3_bib167","doi-asserted-by":"crossref","unstructured":"Granata G, Greco A, Iannella G, et al. Posterior reversible encephalopathy syndrome-Insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2015","DOI":"10.1016\/j.autrev.2015.05.006"},{"key":"10.1007\/s13311-015-0393-3_bib168","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/kem319","article-title":"Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma","volume":"47","author":"Mak","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib169","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.semarthrit.2006.01.003","article-title":"Reversible posterior leukoencephalopathy in connective tissue diseases","volume":"35","author":"Min","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/s10165-010-0386-3","article-title":"Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus","volume":"21","author":"Fujieda","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib171","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/ard.60.5.534","article-title":"Reversible posterior leucoencephalopathy syndrome in systemic lupus and vasculitis","volume":"60","author":"Primavera","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-015-0393-3_bib172","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/41.10.1095","article-title":"Long-term complications of systemic lupus erythematosus","volume":"41","author":"Gordon","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib173","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib174","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.38.7.1060","article-title":"Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy","volume":"38","author":"Berger","year":"1988","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13550289509111006","article-title":"Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare","volume":"1","author":"Berger","year":"1995","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-015-0393-3_bib176","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamaneurol.2013.4668","article-title":"JC polyomavirus granule cell neuronopathy in a patient treated with rituximab","volume":"71","author":"Dang","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib177","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/NRL.0b013e318247b868","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with etanercept","volume":"18","author":"Graff-Radford","year":"2012","journal-title":"Neurologist"},{"key":"10.1007\/s13311-015-0393-3_bib178","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib179","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0961203311416693","article-title":"Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency","volume":"21","author":"Pavlovic","year":"2012","journal-title":"Lupus"},{"key":"10.1007\/s13311-015-0393-3_bib180","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib181","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib182","first-page":"100","article-title":"Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications","volume":"13","author":"Greenlee","year":"2006","journal-title":"Int MS J"},{"key":"10.1007\/s13311-015-0393-3_bib183","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0393-3_bib184","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab-treated patients","volume":"68","author":"Rudick","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib185","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0393-3_bib186","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0393-3_bib187","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0393-3_bib188","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0393-3_bib189","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12016-012-8327-x","article-title":"Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia","volume":"43","author":"Brandao","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1007\/s13311-015-0393-3_bib190","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00296-011-2316-x","article-title":"Optic neuritis after infliximab therapy","volume":"33","author":"Faillace","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1007\/s13311-015-0393-3_bib191","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","article-title":"New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review","volume":"32","author":"Matsumoto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib192","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/s10165-011-0498-4","article-title":"Demyelination during anti-TNFalpha therapy for ankylosing spondylitis","volume":"22","author":"Mercieca","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib193","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-015-0393-3_bib194","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10067-013-2419-8","article-title":"Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases","volume":"33","author":"Theibich","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0393-3_bib195","doi-asserted-by":"crossref","unstructured":"Yagita M, Hamano T, Hatachi S, Fujita M. Peripheral neuropathies during biologic therapies. Mod Rheumatol 2013","DOI":"10.3109\/14397595.2013.859770"},{"key":"10.1007\/s13311-015-0393-3_bib196","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1007\/s13311-015-0393-3_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","article-title":"Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story","volume":"234","author":"Caminero","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0393-3_bib198","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0393-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0393-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:50:16Z","timestamp":1761807016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":198,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009479"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0393-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0393-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}